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Background: Very late stent thrombosis (VLST) after bare-metal stent (BMS) implan-
tation is a rare complication. There is emerging evidence suggesting that in-stent
neoatherosclerosis may play a role, but data on clinical characteristics and prognosis of
patients (p) are limited. The aim of this study was to evaluate the profile and outcome of
VLST after BMS implantation treated with percutaneous coronary intervention (PCI).
Methods: From January 2006 to May 2012 a total of 9,582 PCI were performed at our
center. During this period we identified and retrospectively analyzed 30 consecutive p
with angiographically confirmed VLST related to BMS. Minimum follow-up period of 1
year and 2 years was available in 25/30 and 23/30 p, respectively.
Results: Mean age of p was 6013 years, 93% were male, 53% active smokers, 20%
diabetics, 77% had hyperlipidemia and 67% hypertension. Clinical presentation of VLST
after BMS was ST-segment elevation myocardial infarction (STEMI) in 27 cases, and 3 p
(10%) had non-STEMI. Right coronary artery was the most common location of VLST
(57%). Median period from BMS implantation to VLST was 7.9 years (interquartile
range, 6.0-9.9 years) and most of the p (70%) were receiving oral antiplatelet therapy at
the time of VLST (67% aspirin alone, 3% dual antiplatelet). All p with VLST after BMS
underwent successful PCI. Effective thrombus aspiration was achieved in 67% of p and
a new stent was deployed in 83% of p (14 DES, 11 BMS). A significant deterioration of
LVEF occurred in p with VLST related to BMS (646% to 509%; p0.001). Major
adverse cardiac events (cardiovascular death or myocardial infarction) rates were 7%,
20%, and 39% at 30 days, 1-year and 2-year follow-up, respectively. During the 2-year
follow-up period 3 p died and 6 p had a non-fatal myocardial infarction (recurrent stent
thrombosis in 3 p and myocardial infarction not related to prior VLST in 3 p).
Conclusions: VLST after BMS implantation is an uncommon phenomenon, mainly
presented as STEMI, and its treatment with a new PCI is feasible and effective.
Nevertheless new major adverse cardiac events may occur in this group of p at short- and
mid-term follow-up, related to both prior VLST and coronary disease progression.
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Background: The optimal treatment of in-stent restenosis (ISR) after percutaneous
coronary intervention (PCI) with drug-eluting stents (DES) remains an important clinical
challenge to routine PCI practice. We evaluated the long-term outcomes of DES-ISR
according to treatment modality and determined the predictors of recurrent DES-ISR.
Methods: We assessed outcomes in 488 patients with DES-ISR who underwent repeated
revascularization (339 patients; 302 repeated PCI, 37 coronary artery bypass grafting) or
medical treatment (149 patients) between February 2003 and December 2007. Their
long-term adverse outcomes (death; the composite of death or myocardial infarction [MI];
and target-lesion revascularization [TLR]) were compared, and the predictors of recurrent
restenosis after treatment of DES-ISR were evaluated.
Results: During a median follow-up of 37.2 months (interquartile range, 29.8 to 58.4
months), the unadjusted risks of death (2.0% vs 0.7%, p0.82), MI (0.6% vs 0%,
p0.35), and the composite of death or MI (0.9% vs 0.7%, p0.82) did not significantly
differ between the revascularization and medical treatment groups. In contrast, TLR rate
was significantly higher in patients treated with revascularization (7.7% vs 0.7%,
p0.002). After multivariate adjustment using inverse probability of treatment weighting,
overall findings were consistent. Multivariate analysis showed that pattern of restenosis,
diabetes, and treatment modality were significant independent predictors of repeat
restenosis after DES-ISR treatment.
Conclusions: The long-term outcomes of DES-ISR were benign, regardless of treatment
modality selected clinically by the physician. Pattern of restenosis, diabetes, and treatment
modality were significant predictors of repeated DES failure.
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Background: To date, studies of restenosis after percutaneous coronary interventions
(PCI) with bare-metal-stents (BMS) or drug-eluting stents (DES) have not been per-
formed in a very large population undergoing follow-up angiography.
Methods: All patients undergoing successful implantation of coronary stents for de novo
lesions from 1998 to 2009 and control angiography at 6 out to 8 month-follow-up were
included. Restenotic lesions, cardiogenic shock, dialysis or previous cardiac transplanta-
tion represented exclusion criteria. Data were prospectively collected. Restenosis was
defined as diameter stenosis 50% in the in-segment area at follow-up angiography.
Results: We included 10,004 patients with 15,004 target lesions. At multivariate analysis
PCI with DES was the strongest predictor of restenosis (odds ratio - OR 0.28 [95%
Confidence intervals, 0.25-0.31]). Other correlates were vessel size (1.59 [1.51-1.68] for
each 0.5-mm decrease), stenosis severity (1.03 [1.02-1.05] for each 5% increase), history
of by-pass surgery (1.38 [1.20-1.58]), diabetes mellitus (1.32 [1.19-1.46]), left-main (1.35
[1.02-1.81]), B2/C lesions (1.35 [1.20-1.51]) and long-segment stenting (1.27 [1.21-
1.33]). First-generation DES was less prone to restenosis as compared to BMS.
Second-generation versus first-generation DES further reduced restenosis.
Conclusions: Drug-eluting stents and small vessel size represent the strongest predictors
of restenosis. Second-generation DES has superior anti-restenotic efficacy as compared
with first-generation DES.
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Background: Instent restenosis (ISR) of DES is a growing problem. Data on the
outcomes of EES compared to the first generation DES for the treatment of DES ISR are
lacking. We compared the outcomes of EES to the first generation DES [Paclitaxel eluting
stents (PES) or Sirolimus eluting stents (SES)] for the treatment of DES ISR.
Methods: Patients who underwent percutaneous coronary intervention (PCI) with EES,
SES or PES for the treatment of DES ISR at our institution between 1/2008 and 12/2011
were included. We compared EES versus SES/PES for treating DES ISR. In a Cox
regression analysis; after adjusting for clinical, angiographic and procedural characteris-
tics, a combined primary endpoint of death, myocardial infarction (MI) and target lesion
revascularization (TLR) was was used. Individual components of the primary endpoint,
stent thrombosis & target vessel revascularization (TVR) were secondary endpoints.
Results: Over 4 years, 277 patients had PCI for DES ISR, of which 146 were treated with
EES and 131 with SES/PES. The 2 groups were well matched with respect to age, gender,
smoking history, prevalence of diabetes, COPD, dyslipidemia, renal failure, lesion length
and reference vessel and stent diameter. There were 51 cumulative events over a mean
follow up of 28  14 months. EES was associated with lower frequency of the primary
endpoint compared to SES/PES for treatment of DES ISR (16% vs. 22%), however this
was not statistically significant (p0.4). The individual secondary endpoints of death (4%
vs 10%, p0.06), TLR (13% vs.12%, P 0.85), MI (8% vs 5%, P 0.33), TVR (3.4%
vs 3.1%, p1.0) were not different between EES and SES/PES groups.
Conclusions: EES is associated with similar death, MI, or TLR when compared to
SES/PES for the treatment of DES ISR. TLR rates remain high for DES ISR even in the
second generation DES era, highlighting the need for aggressive risk factor modification
and other potential therapies.
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